Skip to content

Acquisitions at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.04B+304,000%
Stryker logo
StrykerSYK
$22M-99.5%
Haemonetics logo
HaemoneticsHAE
$60.18M
Merit Medical Systems logo
Merit Medical SystemsMMSI
$1M0.0%
Globus Medical logo
Globus MedicalGMED
$4.91M-1.8%
Edwards Lifesciences logo
Edwards LifesciencesEW

Other financials

Income statement

See full
Revenue$5.2B+11.6%
Gross profit$3.6B+12.6%
Operating income$1.1B+19.5%
Net income$1.3B+99.3%
EPS (diluted)$0.90+100%

Balance sheet

See full
Cash & equivalents$850.0M+146%
Total debt$659.0M-94.1%
Total equity$25.9B+16.4%
Total assets$44.4B+10.5%

Cash flow

See full
Operating cash flow$348.0M-35.7%
CapEx$177.0M-5.3%
Free cash flow$171.0M-51.7%

Valuation

See full
Market cap$63.44B-56.6%
P/E17.8×-40.8×
P/S3.1×-4.8×

Profitability

See full
Gross margin69.2%+0.5pp
Operating margin18.4%+2.2pp
Net margin17.3%+5.7pp
FCF margin16.9%-0.3pp

Returns & leverage

See full
Return on equity14.8%+5.2pp
Debt / equity-0.5×
Current ratio1.9×+0.4×

Where this comes from

Reported directly by Boston Scientific in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired.

The official record: Boston Scientific’s 10-Q, filed May 1, 2026, on SEC EDGAR. View the filing →

Ask your AI about Boston Scientific's acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Boston Scientific's acquisitions?
Boston Scientific (BSX) reported acquisitions of $523M in Q1 2026.
How has Boston Scientific's acquisitions changed year-over-year?
Boston Scientific's acquisitions increased by 118.8% year-over-year, from $239M to $523M.
What is the long-term trend for Boston Scientific's acquisitions?
Over 3 years (2021 to 2025), Boston Scientific's acquisitions has grown at a -11.0% compound annual growth rate (CAGR), from $2.26B to $1.59B.
What does acquisitions mean?
Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.